Theralase Technologies Inc. V.TLT

RE:RE:RE:RE:RE:Another therapeutic for COVID

[Rumpl3StiltSkin]

Great discussion guys,
Merry Christmas!

I really hope that TLT can figure out how to roll out a Covid therapeutic that is simple to use in the clinics. We know 1433 is safe. We also know it should be effective. I also believe it can be used as a preventative? And it shouldn't matter too much what Covid 19 morphs into?

tdon1229 wrote:

CancerSlayer wrote:

tdon1229 wrote:

Pandora wrote:

tdon1229 wrote:

Pandora, take note

https://www.hhs.gov/about/news/2020/12/23/hhs-dod-collaborate-with-merck-continue-development-large-scale-manufacturing-investigational-covid-19-treatment.html


 

Yes, collaborating with big money pharma again. In the meantime Cytodyn (CYDY) has done a trial on the mild to mid group and have just completed a blinded study on severe to critical patients (390) with results to be posted mid-January. No collaboration there even though it has possibly the best results of any therapeutic thus far -- but having to wait for numbers.

They have also now started a trial for what is termed the "long-haulers".

https://finance.yahoo.com/news/fda-resumes-eind-approval-severe-110000503.html
 

 

 

And when they realize that CCR5 is over expressed in the brains of stroke victims, maybe they'll get still another trial opportunity with leronlimab, which is a CCR5 agonist.

 

 

 

Hi Tdon.  Just wanted to clarify Leronlimab is a CCR5 "antagonist", which is probably what you meant.  Controlling the exaggerated immune response or cytokine/chemokine storm will play a major role in treating the severely ill/hospitalized. 

Theralase has a realistic opportunity to reduce hospitalizations in the future with its focus on an alternative/better vaccine & potential outpatient therapeutic.  Also, unlike many immunomodulators, gene therapies & other single-target antivirals, the multimodal mechanism of action of TLD-1433/PDT may reduce selection pressure/pathogen resistance.  

I see organometallics making significant strides in medicine...and Ruthenium & its assorted ligands are at the top of a short list.  Throw in optimized PDT or targeted radiation, we may just be on the verge of a "universal" treatment/medical breakthrough...All imo.

 

 

 

Yes, CS, a "CCR5 antagonist" is what I meant to say ... my dancing fingertips skipped over a few letters and changed the meaning.  Thank you for pointing that out.  

As for the potential for a universal treatment, from your lips to God's ear.  However, until Theralase gets some SP traction, or gains a partnership or three, progress towards that goal will be limited by financial concerns and will continue to be painstakingly slow.